Merck & Co., Inc. (MRK) Stock Price & Analysis
Merck & Co., Inc. (MRK) closed at USD 147.24 on Thursday, October 22, 2026, down 1.76% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 149.88; the Oct 22, 2026 session ranged USD 144.07–154.02 on volume of 19,024,624 shares. Market capitalization is $363.27B, with a 52-week range of USD 82.01–156.92 (NYQ). Source: Nexqual, retrieved October 23, 2026 at 09:23 UTC.
Also available as compact Markdown for AI agents: nexqual.com/MRK.md
Key facts (MRK)
- Last four reported quarters (through Jun 30, 2026): revenue $66.6B, net income $3.17B (4.8% margin), free cash flow $16.1B (SEC filings).
- Valuation: P/E 114.5x (avg 263.4x at the last 3 fiscal year-ends), net debt $46.8B.
- 10 of 80 tracked superinvestors hold MRK (13F, Q2 2026 (1 investor on Q3 2026, filed early)): 0 new, 2 added, 4 reduced, 4 unchanged.
- Analysts: Buy (mean 2.11 on a 1–5 scale) (27 analysts), mean target USD 158.56 (range 105–186).
- Total return with dividends: 1Y +73.8% vs S&P 500 +14.9%; 5Y +111.4% vs S&P 500 +80.3%.
- Next earnings: 2026-10-29, EPS estimate USD 2.09, revenue estimate $17.3B.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (MRK)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $48.7B | $59.3B | $60.1B | $64.2B | $65.0B | $66.6B |
| Gross profit | $35.1B | $41.9B | $44.0B | $49.0B | $48.6B | — |
| Net income | $13.0B | $14.5B | $365M | $17.1B | $18.3B | $3.17B |
| EPS (diluted) | $5.14 | $5.71 | $0.14 | $6.74 | $7.28 | — |
| Free cash flow | $8.67B | $14.7B | $9.14B | $18.1B | $12.4B | $16.1B |
| Gross margin | 72.0% | 70.6% | 73.2% | 76.3% | 74.8% | — |
| Net margin | 26.8% | 24.5% | 0.6% | 26.7% | 28.1% | 4.8% |
| Revenue growth | +17.3% | +21.7% | +1.4% | +6.7% | +1.3% | — |
| Cash + short-term investments | $8.10B | $13.2B | $7.09B | $13.7B | $14.6B | — |
| Total debt | $33.1B | $30.7B | $35.1B | $37.1B | $49.3B | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (MRK)
P/E 114.5x · P/S 5.5x · EV/Sales 6.2x · P/FCF 22.6x · P/B 8.7x · FCF yield 4.42% · Earnings yield 0.87% · Dividend yield (paid, TTM) 2.28% · Buyback yield (TTM) 1.16% · Net debt $46.8B · EV $410B
P/E at fiscal year-ends: Dec 2025 14.5x, Dec 2024 14.8x, Dec 2023 760.8x.
Superinvestors (SEC 13F-HR, Q2 2026) (MRK)
10 of 80 tracked investors hold MRK (1 investor on Q3 2026, filed early). Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change | Quarter |
|---|---|---|---|---|---|
| Kahn Brothers | Kahn Brothers Group | 4.85% | $27.3M | Unchanged | Q2 2026 |
| Bill Nygren | Oakmark Funds | 2.06% | $1.55B | Reduced -2.4% | Q2 2026 |
| Sarah Ketterer | Causeway Capital Management | 1.33% | $123M | Added +11.8% | Q2 2026 |
| Prem Watsa | Fairfax Financial Holdings | 0.84% | $22.2M | Unchanged | Q2 2026 |
| Christopher Bloomstran | Semper Augustus | 0.65% | $5.7M | Unchanged | Q2 2026 |
| Mairs & Power | Mairs & Power Funds | 0.06% | $6.6M | Added +2.3% | Q2 2026 |
| David Katz | Matrix Asset Advisors | 0.02% | $236K | Reduced -3.0% | Q3 2026 |
| Dodge & Cox Funds | Dodge & Cox | 0.01% | $17.4M | Reduced -0.2% | Q2 2026 |
| Richard Pzena | Pzena Investment Management | <0.01% | $323K | Unchanged | Q2 2026 |
| Thomas Russo | Gardner Russo & Quinn | <0.01% | $211K | Reduced -23.3% | Q2 2026 |
Analysts (MRK)
Consensus Buy (mean 2.11 on a 1–5 scale), 27 analysts; mean target USD 158.56 (low 105, high 186).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-12 | Citigroup | Target raised | Neutral | $125 → $145 |
| 2026-10-12 | RBC Capital | Target lowered | Sector Perform | $150 → $145 |
| 2026-10-08 | Cantor Fitzgerald | Target raised | Neutral | $120 → $145 |
| 2026-10-07 | Morgan Stanley | Target lowered | Overweight | $179 → $177 |
| 2026-10-05 | JP Morgan | Target raised | Overweight | $150 → $165 |
| 2026-09-29 | Scotiabank | Target raised | Sector Outperform | $155 → $180 |
| 2026-09-10 | HSBC | Target raised | Buy | $150 → $172 |
| 2026-09-09 | Leerink Partners | Target raised | Outperform | $127 → $161 |
| 2026-09-08 | Guggenheim | Target raised | Buy | $146 → $170 |
| 2026-09-04 | Wells Fargo | Target raised | Overweight | $150 → $170 |
| 2026-08-25 | Wolfe Research | Target raised | Outperform | $155 → $180 |
| 2026-08-25 | Argus Research | Target raised | Buy | $145 → $170 |
Total return (dividends reinvested) (MRK)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | +73.8% | +111.4% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +74.2% | +16.1% |
| Volatility (annualized) | 29.2% | 25.5% |
| Max drawdown | -11.4% (Apr 2026→Apr 2026) | -40.7% (Mar 2024→May 2025) |
MRK revenue by business segment (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| Pharmaceutical | $14.76B | 89.3% | +5.1% |
| Animal Health | $1.77B | 10.7% | +7.8% |
| Total revenue | $16.54B | 100% | — |
MRK revenue by product line (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| Keytruda | $7.90B | 47.8% | -0.7% |
| Gardasil Gardasil9 | $1.17B | 7.1% | +3.8% |
| Livestock | $1.04B | 6.3% | +8.3% |
| Companion Animal | $734.0M | 4.4% | +7.2% |
| Other Pharmaceutical | $643.0M | 3.9% | -8.5% |
| Pro Quad MMRII Varivax | $592.0M | 3.6% | -2.8% |
| Winrevair | $588.0M | 3.6% | +75.0% |
| Bridion | $497.0M | 3.0% | +7.8% |
| Keytruda Qlex | $463.0M | 2.8% | — |
| Alliancerevenue Lynparza | $365.0M | 2.2% | -1.4% |
| Prevymis | $295.0M | 1.8% | +29.4% |
| Lenvima | $283.0M | 1.7% | +6.8% |
| Welireg | $271.0M | 1.6% | +67.3% |
| Januvia | $258.0M | 1.6% | -30.6% |
| Ohtuvayre | $204.0M | 1.2% | — |
| Capvaxive | $184.0M | 1.1% | +42.6% |
| Janumet | $171.0M | 1.0% | -31.9% |
| Vaxneuvance | $148.0M | 0.9% | -35.4% |
| Rotateq | $134.0M | 0.8% | +10.7% |
| Alliance Revenue Adempas Verquvo | $126.0M | 0.8% | +2.4% |
| Alliance Revenue Reblozyl | $122.0M | 0.7% | +14.0% |
| Delstrigo | $101.0M | 0.6% | +21.7% |
| Adempas | $78.0M | 0.5% | -2.5% |
| Zerbaxa | $77.0M | 0.5% | +4.1% |
| Isentress Isentress HD | $60.0M | 0.4% | -30.2% |
| Dificid | $22.0M | 0.1% | -77.1% |
| Alliance Revenue Koselugo | $10.0M | 0.1% | -76.7% |
| Lagevrio | $5.0M | 0.0% | -94.0% |
| Total revenue | $16.54B | 100% | — |
MRK revenue by region (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| U.S. | $9.36B | 56.6% | +6.1% |
| Non-US | $7.17B | 43.4% | +4.4% |
| Europe, Middle East and Africa | $3.92B | 23.7% | +7.1% |
| Latin America | $875.0M | 5.3% | +1.9% |
| Asia Pacific (other than China and Japan) | $820.0M | 5.0% | +4.5% |
| Other | $640.0M | 3.9% | +7.6% |
| Japan | $577.0M | 3.5% | -7.8% |
| China | $408.0M | 2.5% | -8.5% |
| Total revenue | $16.54B | 100% | — |
As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).
MRK suppliers, customers and competitors (named in its 10-K)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Customer | McKesson (MCK) | “The Company's customers with the largest accounts receivable balances are: McKesson Corporation, Cencora, Inc. and Cardinal Health, Inc., which represented approximately 22%, 21% and 13%, respectively, of total accounts receivable at December 31, 2025.” |
| Customer | Cencora (COR) | “The Company's customers with the largest accounts receivable balances are: McKesson Corporation, Cencora, Inc. and Cardinal Health, Inc., which represented approximately 22%, 21% and 13%, respectively, of total accounts receivable at December 31, 2025.” |
| Customer | Cardinal Health (CAH) | “The Company's customers with the largest accounts receivable balances are: McKesson Corporation, Cencora, Inc. and Cardinal Health, Inc., which represented approximately 22%, 21% and 13%, respectively, of total accounts receivable at December 31, 2025.” |
| Partner | ASTRAZENECA PLC (AZN) | “(2) Being jointly developed and commercialized in a worldwide collaboration with AstraZeneca.” |
| Partner | Moderna (MRNA) | “Intismeran autogene is being developed as part of a collaboration with Moderna, Inc.” |
| Partner | Sanofi (SNY) | “The Company manufactures a hepatitis B vaccine (Recombivax HB, Hepatitis B Vaccine [Recombinant]) and, subject to a collaboration agreement with Sanofi Pasteur MSD, co-promotes a hexavalent vaccine that includes a hepatitis B component (Vaxelis, Diphtheria and Tetanus Toxoids and Acellular Pertussis, Inactivated Poliovirus, Haemophilus b Conjugate and Hepatitis B Vaccine).” |
| Partner | Pfizer (PFE) | “The application is based on data from the Phase 3 KEYNOTE-905 trial conducted in collaboration with Pfizer and Astellas.” |
Quoted from the company's 10-K filed Feb 24, 2026.
Companies that name MRK in their SEC reports
| Relationship to MRK | Company | Filing | Sentence |
|---|---|---|---|
| competitor | Incannex Healthcare Inc. (IXHL) | 10-K Sep 25, 2026 | “Hoffmann-La Roche AG, Bristol Myers Squibb, AstraZeneca PLC, and Merck & Co., Inc. While we believe we have identified the potential for IHL-675A to more effectively reduce pain and increase quality of life in addition to, or in place of, these existing therapies and the current standard of care, IHL-675A will compete with or complement these other therapeutic options.” |
| partner | Neuphoria Therapeutics Inc. (NEUP) | 10-K Sep 18, 2026 | “The collaboration includes MK-4334, which has completed Phase 1 studies, and MK-1167, which was evaluated in a now-terminated Merck-led Phase 2 trial in Alzheimer's disease dementia following an interim efficacy analysis.” |
| competitor | iBio, Inc. (IBIO) | 10-K Aug 28, 2026 | “Our most significant competitors, among others, are fully integrated pharmaceutical companies such as Eli Lilly and Company, Novo Nordisk A/S, Amgen Inc., Bristol-Myers Squibb Company, Merck & Co., Inc., Novartis AG, MedImmune, LLC (a wholly owned subsidiary of AstraZeneca PLC), Johnson & Johnson, Pfizer Inc., Merck KGaA and Sanofi SA, and more established biotechnology companies such as Genentech, Inc. (a member …” |
| competitor | PHIBRO ANIMAL HEALTH CORP (PAHC) | 10-K Aug 26, 2026 | “Some of our principal competitors include Boehringer Ingelheim International GmbH, Ceva Santé Animale, Elanco Animal Health Incorporated, Huvepharma Inc., Merck & Co., Inc. (Merck Animal Health and MSD Animal Health), Southeastern Minerals, Inc. and Zoetis.” |
| partner | BIO-TECHNE Corp (TECH) | 10-K Aug 24, 2026 | “On June 25, 2026, the Company entered into the Agreement and Plan of Merger (the "Merger Agreement"), with Merck KGaA, Darmstadt, Germany, a German corporation with general partners ("Parent") and EMD Holdings NewCo, Inc. ("Merger Sub"), a Minnesota corporation and a wholly-owned subsidiary of Parent.” |
| partner | ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG) | 20-F Apr 29, 2026 | “a collaboration and license agreement with Innovent and clinical collaboration agreements with AstraZeneca, Merck, and Pfizer, and research” |
| partner | Burning Rock Biotech Ltd (BNR) | 20-F Apr 28, 2026 | “Our products are recognized by the medical, pharmaceutical and scientific communities, as evidenced by (i) the use of our products by oncology key opinion leaders in clinical trials and research studies they initiate, and (ii) our collaborations on clinical trials and research studies with leading pharmaceutical companies including AstraZeneca (NYSE: AZN), Bayer (ETR: BAYN), Johnson & Johnson (NYSE: JNJ), CStone (…” |
| competitor | NORTHWEST BIOTHERAPEUTICS INC (NWBO) | 10-K Apr 15, 2026 | “There are also a number of existing drugs used for the treatment of brain cancer that may compete with our product, including, Avastin® (Roche Holding AG), Gliadel® (Eisai Co. Ltd.), and Temodar® (Merck & Co., Inc.), as well as the Optune electro-therapy device (Novocure) and oncolytic viruses.” |
| competitor | GeoVax Labs, Inc. (GOVX) | 10-K Apr 15, 2026 | “We face general market competition from several subsectors of the vaccine development field, including large, multinational pharmaceutical companies including Sanofi, GSK, Merck, Mitsubishi Tanabe, Takeda, and Pfizer; mid-size pharmaceutical companies and emerging biotechnology companies including Dynavax, Novavax, Moderna, BioNTech and Bavarian Nordic; and academic and not-for-profit vaccine researchers and devel…” |
| customer | Adagene Inc. (ADAG) | 20-F Apr 1, 2026 | “To further advance our pipeline, we have also put in place various clinical collaborations, including an agreement with Roche who is sponsoring and conducting a triple combination trial with ADG126, atezolizumab and bevacizumab in first-line hepatocellular carcinoma (HCC), clinical collaboration and supply agreement with Merck who provides pembrolizumab for certain of our combination clinical trials, and agreement…” |
| competitor | MANGOCEUTICALS, INC. (MGRX) | 10-K Apr 1, 2026 | “GROW product, we compete against the much larger pharmaceutical company Merck & Co., which offers the branded hair loss product Propecia,” |
| partner | TuHURA Biosciences, Inc./NV (HURA) | 10-K Mar 31, 2026 | “Clinical collaboration with Merck” |
| partner | Cocrystal Pharma, Inc. (COCP) | 10-K Mar 31, 2026 | “Aspects of this program were developed in collaboration with Merck, which is legally protecting the intellectual property of the collaboration” |
| partner | Kairos Pharma, LTD. (KAPA) | 10-K Mar 31, 2026 | “and Asia, raised $100 million in equity, and set up partnerships with Merck, Fosun Pharma, Tasly Pharma, and Kalbe Pharma.” |
| supplier | TOMI Environmental Solutions, Inc. (TOMZ) | 10-K Mar 31, 2026 | “On August 12, 2025, we announced a major new customer in the eye health sector, comparable in scale to Pfizer and Merck, who implemented SteraMist iHP at two facilities in under four months and placed open BIT Solution orders for 2026.” |
MRK company outlook (results filed Aug 4, 2026)
- “Financial Outlook - Narrows and Raises Expected Worldwide Sales Range To Be Between $66.3 Billion and $67.3 Billion - Now Expects Non-GAAP EPS To Be Between $2.66 and $2.76;”
Quoted word-for-word from the SEC 8-K results press release.
MRK analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $2.09 | $2.28 | -8.2% | $17.35B | 19 |
| Next quarter (ends Dec 2026) | $1.96 | $1.99 | -1.6% | $16.79B | 17 |
| Current fiscal year (ends Dec 2026) | $2.66 | $2.74 | -3.1% | $67.05B | 25 |
| Next fiscal year (ends Dec 2027) | $9.26 | $9.66 | -4.1% | $69.94B | 22 |
MRK options: expected move
Options price a move of about ±5.6% (±$8.28) by Oct 30, 2026, which includes earnings on Oct 29, 2026. Over the last 8 reports the stock moved ±3.4% on average.
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Oct 30, 2026 | 7 | 47.2% | ±5.6% |
| Nov 6, 2026 | 14 | 42.0% | ±6.8% |
| Nov 13, 2026 | 21 | 37.2% | ±7.3% |
| Nov 20, 2026 | 28 | 36.0% | ±8.1% |
| Nov 27, 2026 | 35 | 34.8% | ±8.7% |
| Dec 4, 2026 | 42 | 33.4% | ±9.1% |
| Dec 18, 2026 | 56 | 32.7% | ±10.6% |
| Jan 15, 2027 | 84 | 32.7% | ±12.7% |
30-day implied volatility 35.8% vs 26.3% realized over the last 30 trading days. Put/call ratio (volume) 0.34. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of October 23, 2026 at 09:23 UTC)
| Price | USD 147.24 |
|---|---|
| Change | ▼ 1.76% (down) |
| Previous Close | USD 149.88 |
| Open | USD 151.05 |
| Day Range | USD 144.07 – 154.02 |
| 52-Week Range | USD 82.01 – 156.92 |
| Volume | 19,024,624 shares |
| Market Cap | $363.27B |
| Exchange | NYQ |
Technical Analysis (MRK)
Nexqual's technical model rates MRK "STRONG BUY" based on 5 bullish and 0 bearish signals across 127 daily candles, as of October 23, 2026 at 09:23 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 51.01 (neutral) |
| vs SMA50 | Above (USD 146.45) |
| MACD | 0.56 (positive) |
Analyst Ratings (MRK)
Wall Street analysts rate MRK "Buy" based on 27 analysts, with a mean price target of USD 158.56 (range USD 105–186), per Nexqual as of October 23, 2026 at 09:23 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 27 |
| Mean Target | USD 158.56 |
| High Target | USD 186 |
| Low Target | USD 105 |
| Buy / Hold / Sell | 19 / 8 / 0 |
Earnings (MRK)
| Next Earnings Date | 2026-10-29 |
|---|---|
| EPS Estimate | USD 2.09 |
| Revenue Estimate | $17.35B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.13 vs est -0.26 ▲ beat |
| 2026-03-31 | USD -1.28 vs est -1.47 ▲ beat |
| 2025-12-31 | USD 2.04 vs est 2.01 ▲ beat |
| 2025-09-30 | USD 2.58 vs est 2.35 ▲ beat |
Source: Nexqual, October 23, 2026 at 09:23 UTC.
Financials & Fundamentals (MRK)
| Total Revenue | $66.57B |
|---|---|
| Revenue Growth (latest quarter, YoY) | +5.10% |
| Gross Margin | +75.90% |
| Operating Margin | -0.24% |
| Profit Margin | +4.77% |
| ROE | +6.96% |
| Debt / Equity | 1.28 |
| Current Ratio | 1.32 |
| Total Cash | $7.14B |
| Total Debt | $53.91B |
| Free Cash Flow (last four quarters to Jun 2026, SEC 10-Q / 10-K) | $16.06B (24.1% of revenue) |
Source: Nexqual, October 23, 2026 at 09:23 UTC.
Financial Health Score (MRK)
Nexqual rates Merck & Co., Inc.'s overall financial health "Mixed" across five dimensions, as of October 23, 2026 at 09:23 UTC.
| Growth | Mixed — Revenue +1.3% YoY (annual), slow |
|---|---|
| Profitability | Solid — Gross margin 76%, operating -0% (last 12 months) |
| Balance Sheet | Mixed — $7.14B cash and investments vs $53.9B debt (Jun 2026, SEC) |
| Cash Flow | Strong — FCF $16.1B (last 4 quarters to Jun 2026, SEC), 24% margin |
| Efficiency | Mixed — ROE 7%, ROA 11.9% |
Ownership (MRK)
| Insider Ownership | +0.06% |
|---|---|
| Institutional Ownership | +82.90% |
| Shares Outstanding | 2.47B |
| Float | 2.46B |
| Short % of Float | +1.15% |
Source: Nexqual, October 23, 2026 at 09:23 UTC.
Leadership (MRK)
Merck & Co., Inc. is led by Robert M. Davis, Chairman, President & CEO, per Nexqual as of October 23, 2026 at 09:23 UTC.
| Chairman, President & CEO | Robert M. Davis |
|---|---|
| Executive VP & CFO | Caroline A. Litchfield |
| Executive VP & President of Merck Research Laboratories | Dean Y. Li |
| Executive Vice President and Chief Information & Digital Officer | Gaurav K. Gupta |
| Vice President of Investor Relations | Peter Dannenbaum |
Major Backers & Investors (MRK)
Notable institutional backers of Merck & Co., Inc. include Wellington Management, Charles Schwab Investment Management, Inc., Morgan Stanley, according to Nexqual as of October 23, 2026 at 09:23 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Wellington Management | 3.5% |
| Charles Schwab Investment Management, Inc. | 2.2% |
| Morgan Stanley | 1.97% |
| FMR, LLC | 1.84% |
| JPMorgan | 1.78% |
| Fidelity | 1.3% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 9.29% |
| BlackRock | 9.2% |
| State Street | 4.88% |
| Geode Capital | 2.46% |
Source: Nexqual, October 23, 2026 at 09:23 UTC.
From Merck & Co., Inc.'s Latest SEC 10-K Filing (filed 2026-02-24)
Key Strengths & Strategy (as disclosed to the SEC)
- Department of Health and Human Services (HHS) has stated that immunizations for all of the diseases covered by the previous immunization schedule will still be available to anyone who wants them through Affordable Care Act insurance plans and federal insurance programs, including Medicaid, the Children's Health Insurance Program, and the VFC program.
Partnerships
- The Company manufactures a hepatitis B vaccine (Recombivax HB, Hepatitis B Vaccine [Recombinant]) and, subject to a collaboration agreement with Sanofi Pasteur MSD, co-promotes a hexavalent vaccine that includes a hepatitis B component (Vaxelis, Diphtheria and Tetanus Toxoids and Acellular Pertussis, Inactivated Poliovirus, Haemophilus b Conjugate and Hepatitis B Vaccine).
- Set forth below is a summary of significant product approvals received by the Company in 2025 and, to date, in 2026. (1) Keytruda Qlex is available in some markets as Keytruda SC. (2) Being jointly developed and commercialized in a worldwide collaboration with AstraZeneca.
Legal & Regulatory Risks (Item 1A, quoted)
- The Company is currently subject to a number of government laws and regulations and, in the future, could become subject to new government laws and regulations.
- The Company is subject to evolving and complex tax laws, which may result in additional liabilities that may affect results of operations and financial condition.
- Adverse outcomes in current or future legal matters could negatively affect the Company's business.
- Current or future litigation, claims, proceedings and government investigations could preclude or delay the commercialization of the Company's products or could adversely affect the Company's business, results of operations, cash flows, financial condition and prospects.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| NVS | Novartis AG | USD 156.27 | ▲ 1.52% |
| ABBV | AbbVie Inc. | USD 285.19 | ▲ 0.14% |
| AZN | AstraZeneca PLC | USD 172.57 | ▲ 2.45% |
| AMGN | Amgen Inc. | USD 447.28 | ▲ 2.04% |
| JNJ | Johnson & Johnson | USD 267.61 | ▲ 3.81% |
| GILD | Gilead Sciences, Inc. | USD 157.19 | ▲ 2.36% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 09:23 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt